Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 222

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 222
---
 Appointment

Each non-executive director
(other than Dr. Parker) has been appointed to serve on our Board of Directors pursuant to a letter of appointment. The initial term of
appointment for each director is three years, unless terminated earlier by either party upon one month’s prior notice or in accordance
with the terms of the letters of appointment. The appointment is subject to our articles of association, and is subject to confirmation
at any annual general meeting of the Company.

| 110 |

Each non-executive director
(other than Dr. Parker) was paid an annual fee of £40,000 in 2024, which covers all duties, including committee service or service
on the board of a Biodexa subsidiary, with the exception of committee chairmanships and certain additional responsibilities, such as taking
on the role of senior independent director. This amount may be changed from time to time. In addition, we reimburse each director for
reasonable and properly documented expenses incurred in performing their duties. As noted above, we also grant each director a deed of
indemnity against certain liabilities that may be incurred as a result of their service, to the extent permitted by the Companies Act.

In addition, without our prior
written consent, for a period of six months following a director’s termination from service, such director will not, whether as
a principal or agent and whether alone or jointly with, or as a director, manager, partner, shareholder, employee consultant of, any other
person, carry on or be engaged, concerned or interested in any business which is similar to or which is (or intends to be) in competition
with any business being carried on by Biodexa or any subsidiary, as applicable.

Dr. Parker Letter of Appointment

Pursuant to a term of appointment
dated June 20, 2022, or the Appointment Agreement, Dr. Parker was appointed Non-Executive Chairman of the Board of Directors, effective
as of the date thereof. The initial term of appointment for Dr. Parker expired on June 19, 2023 and was subsequently renewed for one-year.
In addition, his appointment may be terminated:

| • | by either party giving at least three months prior written notice; |

| • | by the Board of Directors reasonably determining that Dr. Parker’s acceptance of any other employment,                                   
 engagement, appointment, interest or involvement with any business or person competes or conflicts with his appointment and would result 
 in a serious conflict of interest or Dr. Parker reasonably